Evidence map›Paper›PMID 32062805›Full record

ArticleWorld journal of urology2020

Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.

Beppe Calò, Ugo Falagario, Francesca Sanguedolce, Alessandro Veccia, Marco Chirico, Emanuel Carvalho-Diaz, Paulo Mota, Estêvão Lima, Riccardo Autorino, Giuseppe Carrieri and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Beppe CalòDepartment of Urology and Renal Transplantation, University of Foggia, Foggia, Italy. b.calo@hotmail.it.
Ugo FalagarioDepartment of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
Francesca SanguedolceDepartment of Pathology, University of Foggia, Foggia, Italy.
Alessandro VecciaDivision of Urology, Department of Surgery, VCU Health, Richmond, VA, USA.
Marco ChiricoDepartment of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
Emanuel Carvalho-DiazDepartment of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal.
Paulo MotaDepartment of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal.
Estêvão LimaDepartment of CUF Urology and Service of Urology, Hospital of Braga, Braga, Portugal.
Riccardo AutorinoDivision of Urology, Department of Surgery, VCU Health, Richmond, VA, USA.
Giuseppe CarrieriDepartment of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
Luigi CormioDepartment of Urology and Renal Transplantation, University of Foggia, Foggia, Italy.
University of Foggia · ITHospital Braga · PTChildren's Hospital of Richmond at VCU · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the impact of time to restaging transurethral resection (Re-TUR) on recurrence-free survival (RFS), progression-free survival (PFS), and cancer specific survival (CSS) of patients with high-grade T1 bladder cancer (BC) treated with intravesical Bacillus Calmette-Guerin (BCG). MATERIALS AND PATIENTS: Our prospectively maintained NMIBC databases were queried to identify patients with high-grade T1 BC who underwent Re-TUR before receiving intravesical BCG treatment (induction + 1-year maintenance). Patients were divided into three groups based on time to Re-TUR (group A: ≤ 6 weeks; group B: > 6-12 weeks; group C: > 12-18 weeks). Kaplan-Meier plots were used to estimate differences in RFS, PFS, and CSS. Multivariate Cox regression analysis was used to assess the impact of time to Re-TUR on oncological outcomes.

resultsOverall, 269 high-grade T1 BC patients were eligible for the analysis. Nineteen (7.1%) had concomitant CIS. Median follow-up was 49.3 (IQR 25-65) months. Kaplan-Meier plots showed no differences in RFS, PFS, and CSS between the three groups. Multivariate Cox regression analysis showed that Group B had a slightly better RFS, while the other outcomes were not affected by time to Re-TUR.

conclusionsThis is the first study testing the role of time to Re-TUR in a homogeneous population of patients with high-grade T1 BC who received complete BCG treatment. The study challenged the concept the sooner the Re-TUR the better, since time to Re-TUR did not significantly affect oncological outcomes.

Indexed as

Adjuvants, ImmunologicAdministration, IntravesicalAgedBCG VaccineCombined Modality TherapyCystectomyDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingProgression-Free SurvivalRetrospective StudiesSurvival RateAdjuvants, ImmunologicBCG VaccineHigh-gradeNon muscle-invasive bladder cancerOncological outcomesRestaging transurethral resectionTime to re-TUR

Identifiers

PMID32062805
OpenAlexW3005576949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.